Horses may have experienced more than one of the observed adverse reactions during the study. The safety of EQUIOXX Tablets is based on a determination of comparable relative bioavailability of the firocoxib tablet to the EQUIOXX Oral Paste. Adverse reactions associated with the ingestion of corticosteroids, should be avoided. The concomitant use of protein bound drugs with EQUIOXX Tablets has not been studied in horses. The influence that the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients. It varies with the individual patient. Horses that have experienced adverse reactions from one NSAID may experience adverse reactions from another. Treatment with EQUIOXX should be terminated if signs such as inappetence, colic, abnormal feces, or lethargy are observed. As a class, cyclooxygenase inhibitors may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug associated adverse events varies with the individual patient. Horses that have experienced adverse reactions from one NSAID may experience adverse reactions from another. The presence of tubulointerstitial nephropathy was considered treatment-related. One horse from the control group and two horses from the 5X group had injection site swellings during treatment. Injection site reactions were consistent with observations seen in horses fed a diet of hay and grain and are not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.

For additional information about adverse drug reaction reporting for animal drugs, contact CDC at 1-866-VETS-4-VETS or visit at http://www.worldvets.org/adverse-reactions-reports.

In the field trials, EQUIOXX Oral Pastes were safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics. Therefore, based on the relative bioavailability of firocoxib across formulations, concomitant use of the EQUIOXX Tablets with other therapies is expected to have the same expectation of safety. All the additional target animal safety or field studies were conducted for EQUIOXX Tablets. The safety data sheet (1030) contains additional occupational safety information. In a two period cross over study conducted to evaluate the relative bioavailability of the tablet to the paste formulation, 30 horses were observed daily for adverse reactions, including early and late clinical reactions, were conducted at specified intervals during each treatment period to assess the effects of firocoxib on the renal and urinal acids. Varying degrees of oral ulcerations, lesions or other minor adverse reactions were noted during the study. However, they were considered to be consistent with oral ulcerations found in the horse and not likely to be related to the use of firocoxib. To report suspected adverse events, for technical assistance, or to obtain a copy of the TGA, contact Merial at 1-877-275-5409.